The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001371381p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
26/10/2026
Date registered
Help: Date registered
16/11/2026
Date last updated
Help: Date last updated
16/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
16/11/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Safety and ease of use of a heat-activated gel mixed with donor bone to rebuild jawbone during dental implant surgery, without a barrier membrane
Scientific title
A Study to Investigate the Safety and Procedural Feasibility of Tegenix Combined with Allograft Corticocancellous Bone Particles for Guided Bone Regeneration During Dental Implant Placement
Additional trial identifiers [1] 318734 0
TP-GBR-001
Universal Trial Number (UTN)
Trial acronym
PET C
Related trial records

Health condition
Health condition(s) studied:
Peri-implant bony dehiscence defect 343962 0
Alveolar bone deficiency 343963 0
Partial edentulism 343964 0
Condition category
Condition code
Oral and Gastrointestinal 340102 340102 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Single-arm. At implant placement (Day 0), once a facial peri-implant bony dehiscence defect is confirmed intraoperatively, the investigator performs guided bone regeneration (GBR) by mixing Tegenix with allograft bone and applying the composite directly to fill the defect, without a cell-occlusive barrier membrane. Tegenix is a sterile, single-use, ready-to-use 1 mL syringe of a synthetic thermoresponsive polymer, PNPHO (poly(N-isopropylacrylamide-co-N-acryloxysuccinimide-co-(2-hydroxyethyl methacrylate-polylactide)-co-oligo(ethylene glycol) monomethyl ether methacrylate)), at 280 mg/mL in phosphate buffered saline. Each 1 mL device is mixed with 2 cc (1 g) of a human allograft corticocancellous bone particle preparation included on the Australian Register of Therapeutic Goods (ARTG) (Oravance corticocancellous bone, ARTG 277310, Australian Biotechnologies Pty Ltd), a 1:1 ratio by weight (1:2 by volume). A maximum of 4 devices (4 mL, about 8 cc of composite) may be used per participant. The polymer gels at body temperature to hold the graft in place and resorbs within about 30 days. Mixing and application of the composite takes approximately 5 minutes, within an implant placement and GBR procedure of approximately 5 -15 minutes. If the composite cannot be positioned as intended, the surgeon may remove it and complete the augmentation conventionally (intraoperative conversion); the participant stays in the study for safety follow-up. The procedure is performed once, by a specialist periodontist. Adherence is ensured by direct intraoperative application and recorded in the electronic case report form (eCRF) with device lot and number of devices used. A research cone beam computed tomography (CBCT) scan no later than Day 7 confirms the composite has stayed in place. Stage II surgery at Month 6 is routine care under local anaesthetic: a flap is raised to expose the implant and grafted site, the cover screw is replaced with a healing abutment, and the flap is stitched closed. While the site is open, the remaining defect is measured, bone quality is graded, implant stability is measured and a trephine core of the regenerated bone is taken for histology. Follow-up continues to Month 20 after GBR.
Intervention code [1] 335630 0
Treatment: Surgery
Description of the comparator or control
No control group. All participants receive the Tegenix and allograft composite.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 347249 0
Incidence and nature of adverse events, including adverse device effects and serious adverse events
Timepoint [1] 347249 0
From the start of the Day 0 guided bone regeneration (GBR) procedure to the end of study visit, assessed at Day 7, Day 14, Month 1, Month 3, Month 6, Month 12 and Month 20 post-GBR (primary timepoint: Month 20 post-GBR)
Primary outcome [2] 347250 0
Incidence of device deficiencies
Timepoint [2] 347250 0
Day 0 (application) to Month 20 post-GBR
Primary outcome [3] 347251 0
Procedural feasibility (composite): time to perform GBR, retention of the composite at the intended site after soft tissue exposure, surgical time and surgical complexity compared with conventional membrane GBR (each scored 1 to 3)
Timepoint [3] 347251 0
Day 0 (immediately after surgery)
Secondary outcome [1] 469692 0
Change in bone dimensions at the augmented site
Timepoint [1] 469692 0
Pre-operatively (screening CBCT, before Day 0) and Month 6 post-GBR (Stage II surgery)
Secondary outcome [2] 469693 0
Clinical bone quality at the augmented site
Timepoint [2] 469693 0
Month 6 post-GBR (Stage II surgery)
Secondary outcome [3] 469694 0
Histological characteristics of newly formed bone: new bone formation, residual graft particles, connective tissue, inflammatory infiltrate and, where the core allows, histomorphometry
Timepoint [3] 469694 0
Month 6 post-GBR (Stage II surgery)
Secondary outcome [4] 469695 0
Soft tissue swelling and oedema at the augmented site
Timepoint [4] 469695 0
Day 7, Day 14, Month 1, Month 3 and Month 6 post-GBR
Secondary outcome [5] 469696 0
Soft tissue dehiscence at the augmented site
Timepoint [5] 469696 0
Day 7, Day 14, Month 1, Month 3 and Month 6 post-GBR
Secondary outcome [6] 469697 0
Change from pre-operative baseline in post-operative pain
Timepoint [6] 469697 0
Day 0 (pre-operative baseline), and Day 1, Day 7, Day 14, Month 1 and Month 3 post-GBR
Secondary outcome [7] 469698 0
Analgesic consumption
Timepoint [7] 469698 0
Day 0, recorded at completion of the GBR procedure
Secondary outcome [8] 469699 0
Surgical time
Timepoint [8] 469699 0
Day 0, recorded at completion of the GBR procedure
Secondary outcome [9] 469700 0
Implant Survival
Timepoint [9] 469700 0
Month 6 (Stage II surgery), Month 12 and Month 20 post-GBR
Secondary outcome [10] 469701 0
Peri-implant health
Timepoint [10] 469701 0
Month 12 and Month 20 post-GBR (after prosthetic restoration)
Secondary outcome [11] 469703 0
Need for secondary bone augmentation
Timepoint [11] 469703 0
Month 6 post-GBR (Stage II surgery)
Secondary outcome [12] 469704 0
Participant satisfaction and patient-reported outcomes
Timepoint [12] 469704 0
Month 20 post-GBR

Eligibility
Key inclusion criteria
Adults aged 18 to 80 years; partially edentulous with at least 1 missing tooth in the maxilla or mandible needing a fixed implant-supported restoration; tooth at the implant site extracted at least 6 weeks earlier with no other surgery at the site (such as ridge preservation); vertical bone height of 8 mm or more and favourable primary implant stability; a facial peri-implant bony dehiscence defect after implant placement requiring simultaneous guided bone regeneration (confirmed intraoperatively); planned Stage II surgery at about 6 months; full mouth plaque score and bleeding on probing of 25% or less; probing depths of 4 mm or less (or deeper without bleeding); willing and able to give written informed consent and attend all visits to Month 20.
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Any condition contraindicating implant surgery or completion of the study, including documented renal disease, planned chemotherapy or radiotherapy, cardiovascular, immune, autoimmune, musculoskeletal, nervous system or metabolic disorders (including uncontrolled diabetes), neoplasm, active infection, or disorders of bone metabolism including antiresorptive or antiangiogenic therapy; smoking more than 10 cigarettes a day or regular vaping; pregnancy, lactation, or women of childbearing potential not using acceptable contraception; psychological condition affecting understanding of the study; another clinical study or investigational product within 4 weeks; current or planned immunosuppressive therapy, including systemic corticosteroids at immunosuppressive doses; mucosal disease or oral lesions likely to impair healing; active infection at or next to the site; previous radiotherapy to the jaws; previous regenerative treatment or materials likely to hinder bone regeneration at the site; known hypersensitivity to any component of Tegenix or the allograft.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Descriptive statistics only; no hypothesis testing. Sample size of 10 is not based on a power calculation and is intended to give descriptive estimates of safety, defect resolution, bone quality and histology, and their variability, to power a later controlled study. No imputation of missing data. A statistical analysis plan will be approved before database lock.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 30396 0
West Perth Periodontics - West Perth
Recruitment postcode(s) [1] 46815 0
6005 - West Perth

Funding & Sponsors
Funding source category [1] 323305 0
Commercial sector/Industry
Name [1] 323305 0
Tetratherix Technology Pty Limited
Country [1] 323305 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Tetratherix Technology Pty Limited
Address
Country
Australia
Secondary sponsor category [1] 326274 0
None
Name [1] 326274 0
Address [1] 326274 0
Country [1] 326274 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 321694 0
St Vincent’s Hospital Human Research Ethics Committee
Ethics committee address [1] 321694 0
Ethics committee country [1] 321694 0
Australia
Date submitted for ethics approval [1] 321694 0
02/11/2026
Approval date [1] 321694 0
Ethics approval number [1] 321694 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 154550 0
Prof DAX CALDER
Address 154550 0
West Perth Periodontics, 21 Rheola Street, West Perth WA 6005
Country 154550 0
Australia
Phone 154550 0
+61 89321 7581
Fax 154550 0
Email 154550 0
Contact person for public queries
Name 154551 0
Clinical Professor Dax Calder,
Address 154551 0
West Perth Periodontics, 21 Rheola Street, West Perth WA 6005
Country 154551 0
Australia
Phone 154551 0
+61893217581
Fax 154551 0
Email 154551 0
Contact person for scientific queries
Name 154552 0
Dr Ali Fathi of Tetratherix Technology Pty Limited
Address 154552 0
Tetratherix Technology - Unit 29, 34–36 Ralph Street, Alexandria NSW 2015. Country: Australia
Country 154552 0
Australia
Phone 154552 0
+61395625333
Fax 154552 0
Email 154552 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: small single-site first-in-human device study under commercial sponsorship; data include identifiable clinical images and CBCT scans; summary results will be reported.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.